This article was originally published in The Tan Sheet
Executive SummaryJapanese pharmaceutical firms terminate plans to form joint holding company that would have created country's third largest drug maker, Tanabe Seiyaku announces Dec. 3. "Differences regarding the most appropriate direction to be pursued post-merger, in addition to the differences existing in the companies' fundamental infrastructure, makes it unlikely for the companies to be able to take full advantage of their respective strengths and specialties or bring increased value to stockholders," Tanabe states. Under the plan, Taisho - Japan's top OTC producer - would have absorbed Tanabe's OTC business, while Tanabe would have integrated Taisho's Rx operations (1"The Tan Sheet" Sept. 24, In Brief)...
You may also be interested in...
HBW Executive Decisions: Perrigo Americas, Nutraceutical International Helm Changes, ABC Farnsworth Award, More
Myos Rens hires Eric LeGrand as special advisor for sports nutrition; Perrigo Consumer Americas chief Jeff Needham will be succeeded by Rich Sorota; Nutraceutical International appoints Monty Sharma to replace Chad Clawson at the helm; American Botanical Council’s Farnsworth Award goes to Rachel Mata; and Herbalife’s John Agwunobi will be chairman as well as CEO.
Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971
It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.